{"product_id":"cooleys-anemia-isbn-9781573317825","title":"Cooley's Anemia","description":"Thanks to scientific advances, individuals with thalassemia—a group of genetic blood disorders which includes Cooley's Anemia — are now living into their 40's and 50's. Not only are individuals living longer, but their quality of life has increased. Scientific and clinical advancements have resulted in new iron-chelating drugs, early detection of organ failure, an understanding of adult complications associated with living with thalassemia (osteoporosis, heart failure, growth hormone deficiency, pulmonary hypertension, and infertility) and promising progress towards the ultimate magic bullet—a cure in the form of bone marrow and cord blood transplants, or gene therapy.\u003cbr\u003e \u003cbr\u003e   \u003cp\u003eThis volume integrates basic science and clinical research so that both scientists and clinicians can develop a mutual understanding of recent progress in thalassemia.\u003c\/p\u003e \u003cp\u003eNOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit \u003ca href=\"http:\/\/www.blackwellpublishing.com\/nyas\"\u003ewww.blackwellpublishing.com\/nyas\u003c\/a\u003e.\u003c\/p\u003e Clinical trials in thalassemia: insights from the patient community \u003cp\u003ePathogenesis and management of iron toxicity in thalassemia\u003c\/p\u003e \u003cp\u003eThe role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia\u003c\/p\u003e \u003cp\u003eThalassemia as a global health problem: recent progress toward its control in the developing countries\u003c\/p\u003e \u003cp\u003eIron metabolism and ineffective erythropoiesis in [beta]-thalassemia mouse models\u003c\/p\u003e \u003cp\u003eHepcidin in [beta]-thalassemia\u003c\/p\u003e \u003cp\u003eTherapy for [beta]-globinopathies: a brief review and determinants for successful and safe correction\u003c\/p\u003e \u003cp\u003eHumanized mouse models of Cooley's anemia: correct fetal-to-adult hemoglobin switching, disease onset, and disease pathology\u003c\/p\u003e \u003cp\u003eStrategy for a multicenter phase I clinical trial to evaluate globin gene transfer in [beta]-thalassemia\u003c\/p\u003e \u003cp\u003eHematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease\u003c\/p\u003e \u003cp\u003eTranscriptional silencing of fetal hemoglobin by BCL11A\u003c\/p\u003e \u003cp\u003eThe challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in [beta]-thalassemia patients\u003c\/p\u003e \u003cp\u003eDeferiprone\u003c\/p\u003e \u003cp\u003eCombined iron chelation therapy\u003c\/p\u003e \u003cp\u003eDeferasirox: current knowledge and future challenges\u003c\/p\u003e \u003cp\u003eMonitoring the efficiency of iron chelation therapy: the potential of nontransferrin-bound iron\u003c\/p\u003e \u003cp\u003eCritical appraisal of growth retardation and pubertal disturbances in thalassemia\u003c\/p\u003e \u003cp\u003eMagnetic resonance assessment of iron overload by separate measurement of tissue ferritin and hemosiderin iron Predicting pituitary iron and endocrine dysfunction\u003c\/p\u003e \u003cp\u003eBetter survival and less cardiac morbidity in female patients with thalassemia major: a review of the literature. A preclinical approach for gene therapy of [beta]-thalassemia\u003c\/p\u003e \u003cp\u003eThe role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation\u003c\/p\u003e \u003cp\u003eProgress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia\u003c\/p\u003e \u003cp\u003eEmerging insights in the management of hemoglobin E beta thalassemia\u003c\/p\u003e \u003cp\u003eFetal globin gene inducers: novel agents and new potential\u003c\/p\u003e \u003cp\u003eDetection of the cardiovascular complications of thalassemia by echocardiography\u003c\/p\u003e \u003cp\u003eCardiovascular MRI in thalassemia major\u003c\/p\u003e \u003cp\u003eComplexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy\u003c\/p\u003e \u003cp\u003eNutritional deficiencies in patients with thalassemia\u003c\/p\u003e \u003cp\u003eFerritin iron minerals are chelator targets, antioxidants, and coated, dietary iron\u003c\/p\u003e \u003cp\u003ePulmonary hypertension in thalassemia\u003c\/p\u003e \u003cp\u003eThe natural history of thalassemia intermedia\u003c\/p\u003e \u003cp\u003eHepcidin and Hfe in iron overload in [beta]-thalassemia\u003c\/p\u003e \u003cp\u003eFertility potential in thalassemia major women: current findings and future diagnostic tools\u003c\/p\u003e \u003cp\u003eRedefining thalassemia as a hypercoagulable state\u003c\/p\u003e \u003cp\u003eTreatment options for thalassemia patients with osteoporosis\u003c\/p\u003e \u003cp\u003eHealth care transition in thalassemia: pediatric to adult-oriented care\u003c\/p\u003e \u003cp\u003eNinth Cooley's Anemia Symposium: summary and perspective. \u003cbr\u003e\u003cbr\u003eClinical trials in thalassemia: insights from the patient community\u003c\/p\u003e \u003cp\u003ePathogenesis and management of iron toxicity in thalassemia\u003c\/p\u003e \u003cp\u003eThe role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia\u003c\/p\u003e \u003cp\u003eThalassemia as a global health problem: recent progress toward its control in the developing countries\u003c\/p\u003e \u003cp\u003eIron metabolism and ineffective erythropoiesis in β-thalassemia mouse models\u003c\/p\u003e \u003cp\u003eHepcidin in β-thalassemia\u003c\/p\u003e \u003cp\u003eTherapy for β-globinopathies: a brief review and determinants for successful and safe correction\u003c\/p\u003e \u003cp\u003eHumanized mouse models of Cooley's anemia: correct fetal-to-adult hemoglobin switching, disease onset, and disease pathology\u003c\/p\u003e \u003cp\u003eStrategy for a multicenter phase I clinical trial to evaluate globin gene transfer in β-thalassemia\u003c\/p\u003e \u003cp\u003eHematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease\u003c\/p\u003e \u003cp\u003eTranscriptional silencing of fetal hemoglobin by BCL11A\u003c\/p\u003e \u003cp\u003eThe challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in β-thalassemia patients\u003c\/p\u003e \u003cp\u003eDeferiprone\u003c\/p\u003e \u003cp\u003eCombined iron chelation therapy\u003c\/p\u003e \u003cp\u003eDeferasirox: current knowledge and future challenges\u003c\/p\u003e \u003cp\u003eMonitoring the efficiency of iron chelation therapy: the potential of nontransferrin-bound iron\u003c\/p\u003e \u003cp\u003eCritical appraisal of growth retardation and pubertal disturbances in thalassemia\u003c\/p\u003e \u003cp\u003eMagnetic resonance assessment of iron overload by separate measurement of tissue ferritin and hemosiderin iron\u003c\/p\u003e \u003cp\u003ePredicting pituitary iron and endocrine dysfunction\u003c\/p\u003e \u003cp\u003eBetter survival and less cardiac morbidity in female patients with thalassemia major: a review of the literature. \u003cbr\u003e\u003cbr\u003eA preclinical approach for gene therapy of β-thalassemia\u003c\/p\u003e \u003cp\u003eThe role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation\u003c\/p\u003e \u003cp\u003eProgress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia\u003c\/p\u003e \u003cp\u003eEmerging insights in the management of hemoglobin E beta thalassemia\u003c\/p\u003e \u003cp\u003eFetal globin gene inducers: novel agents and new potential\u003c\/p\u003e \u003cp\u003eDetection of the cardiovascular complications of thalassemia by echocardiography\u003c\/p\u003e \u003cp\u003eCardiovascular MRI in thalassemia major\u003c\/p\u003e \u003cp\u003eComplexity of alpha thalassemia: growing health problem with new approaches to screening, diagnosis, and therapy\u003c\/p\u003e \u003cp\u003eNutritional deficiencies in patients with thalassemia\u003c\/p\u003e \u003cp\u003eFerritin iron minerals are chelator targets, antioxidants, and coated, dietary iron\u003c\/p\u003e \u003cp\u003ePulmonary hypertension in thalassemia\u003c\/p\u003e \u003cp\u003eThe natural history of thalassemia intermedia\u003c\/p\u003e \u003cp\u003eHepcidin and Hfe in iron overload in β-thalassemia\u003c\/p\u003e \u003cp\u003eFertility potential in thalassemia major women: current findings and future diagnostic tools\u003c\/p\u003e \u003cp\u003eRedefining thalassemia as a hypercoagulable state\u003c\/p\u003e \u003cp\u003eTreatment options for thalassemia patients with osteoporosis\u003c\/p\u003e \u003cp\u003eHealth care transition in thalassemia: pediatric to adult-oriented care\u003c\/p\u003e \u003cp\u003eNinth Cooley's Anemia Symposium: summary and perspective\u003c\/p\u003e \"Overall, the volume provides a good balance of translational research, clinical application such as potential new therapeutic strategies and consideration of the public health concerns that haemoglobin disorders pose, particularly in the developing world.\" (The Bulletin, 1 October 2011)  \u003cp\u003eElliott P. Vichinsky is the editor of Cooley's Anemia: Ninth Symposium, Volume 1202, published by Wiley. Ellis Neufeld is the editor of Cooley's Anemia: Ninth Symposium, Volume 1202, published by Wiley.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47988990738661,"sku":"NP9781573317825","price":149.75,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781573317825.jpg?v=1761782343","url":"https:\/\/k12savings.com\/products\/cooleys-anemia-isbn-9781573317825","provider":"K12savings","version":"1.0","type":"link"}